RRMM – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:44 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg RRMM – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Daratumumab Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-daratumumab-market-2021-2025/ Fri, 04 Jun 2021 06:22:22 +0000 https://www.cri-report.com/?post_type=product&p=11712 The sales of Daratumumab increased from around CNY0.5 million in 2019 to around CNY24.82 million in 2020, with an annual increase of more than 40 times.

The post Investigation Report on China’s Daratumumab Market 2021-2025 first appeared on CRI Report.

]]> Daratumumab, developed by Johnson & Johnson, is a monoclonal antibody available for the treatment of myeloma. Its product DARZALEX was approved for the treatment of patients with multiple myeloma who have received at least one therapy, including a proteasome inhibitor and an immunomodulatory agent. It is the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world. Daratumumab was approved in China in 2019, and by the first half of 2021, Janssen-Cilag International NV(BE) is the only manufacturer in the Chinese Daratumumab market.

According to CRI’s market research, since Daratumumab entered the Chinese market in 2019, its sales have grown rapidly. The sales of Daratumumab increased from around CNY0.5 million in 2019 to around CNY24.82 million in 2020, with an annual increase of more than 40 times.

CRI predicts its sales volume will continue to grow from 2021 to 2025 with the expansion of the Daratumumab market. In 2020, Johnson & Johnson has submitted two applications for the approval of Daratumumab in China for new indications. With the increase in the number of indications, its sales volume will continue to grow. In addition, Daratumumab, a novel human monoclonal antibody, binding CD38, is more effective than bortezomib and lenalidomide. Therefore, the market share of Daratumumab will expand, and sales will continue to rise in the future.

Topics Covered:
-The impact of COVID-19 on China’s Daratumumab market
– Sales value of China’s Daratumumab 2016-2020
– Competitive landscape of China’s Daratumumab market
– Prices of Daratumumab in China
– Prices of Daratumumab in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Daratumumab market
– Prospect of China’s Daratumumab market from 2021 to 2025

The post Investigation Report on China’s Daratumumab Market 2021-2025 first appeared on CRI Report.

]]>